Is “Rescuing Failed Drugs with AI” a Category Now?
Inside the growing bet that AI can find the patients pharma's failed trials missed...
In April, a Toronto-based startup called Biossil came out of stealth with a total of $70 million in funding, co-led by Peter Thiel’s Founders Fund and OpenAI.
Their thesis is a bit different from what most AI biopharma companies are doing. Instead of designing new molecules, Biossil uses AI to dig through late-stage clinical failures and figure out whic…